Skip to main content

Recombinant Human FGF-8f Protein

R&D Systems, part of Bio-Techne | Catalog # 5027-FF

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
5027-FF-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
5027-FF-025

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

E. coli-derived human FGF-8 protein
Gln23-Arg244, with an N-terminal Met

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

25.5 kDa

SDS-PAGE

29 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using NR6R-3T3 mouse fibroblast cells. Rizzino, A. et al. (1988) Cancer Res. 48:4266; Thomas, K. et al. (1987) Methods Enzymol. 147:120.
The ED50 for this effect is 0.04-0.2 µg/mL in the presence of 10 µg/mL of heparin.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 5027-FF
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
Carrier Free: 5027-FF/CF
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: FGF-8

FGF-8, a member of the fibroblast growth factor family, is a secreted heparin-binding protein that was originally discovered as a growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells (1-3). Alternative splicing of mouse FGF-8 mRNA generates eight secreted isoforms, designated a-h, but only FGF-8a, b, e and f exist in humans (4). FGF-8 contains a 22 amino acid (aa) signal sequence, an N-terminal domain that varies according to the isoform (84 aa for FGF-8f, the longest form in humans; 20 aa for the shortest, FGF-8a), a 125 aa FGF domain and a 37 aa proline-rich C-terminal sequence. The FGF domain of FGF-8 shares the most aa identity with FGF-17 (75%) and FGF-18 (67%), and these three form an FGF subfamily (2). Human and mouse FGF-8f share 98% aa identity (4), while the human FGF-8a sequence, which is common to all isoforms, shares 100% aa identity with mouse, rat and bovine FGF-8a, and 99%, 83%, 83% and 78% aa identity with canine, Xenopus, chicken and zebrafish FGF-8a, respectively. FGF-8 is widely expressed during embryogenesis, and mediates epithelial-mesenchymal transition. It plays an organizing and inducing role during gastrulation, and regulates patterning of the midbrain/hindbrain, eye, ear, limbs and heart in the embryo (2, 5-8). The isoforms may play different roles in development. FGF-8a, b and e have transforming activities, although FGF-8b shows the strongest receptor affinity and oncogenic capacity (1, 5, 9, 10). FGF-8 shows limited expression in the normal adult, but low levels are found in the reproductive and genitourinary tract, peripheral leukocytes and bone marrow hematopoietic cells (3, 9, 11).

References

  1. Mattila, M.M. and P.L. Harkonen (2007) Cytokine Growth Factor Rev. 18:257.
  2. Reuss, B. and O. von Bohlen und Halbach (2003) Cell Tissue Res. 313:139.
  3. Tanaka, A. et al. (1992) Proc. Natl. Acad. Sci. USA 89:8928.
  4. Gemel, J. et al. (1996) Genomics 35:253.
  5. Olsen, S.K. et al. (2006) Genes Dev. 20:185. 
  6. Crossley, P.H. et al. (1996) Cell 84:127.
  7. Heikinheimo, M. et al. (1994) Mech. Dev. 48:129.
  8. Sun, X. et al. (1999) Genes Dev. 13:1834.
  9. Ghosh, A.K. et al. (1996) Cell Growth Differ. 7:1425.
  10. Mattila, M.M. et al. (2001) Oncogene 20:2791.
  11. Nezu, M. et al. (2005) Biochem. Biophys. Res. Commun. 335:843.

Long Name

Fibroblast Growth Factor 8

Alternate Names

AIGF, FGF8, HBGF-8

Entrez Gene IDs

2253 (Human); 14179 (Mouse); 29349 (Rat)

Gene Symbol

FGF8

UniProt

Additional FGF-8 Products

Product Documents for Recombinant Human FGF-8f Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human FGF-8f Protein

For research use only

Loading...
Loading...
Loading...